Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 807 results for "daiichi sankyo company"

Daiichi Sankyo launches new formulation of anti-thrombotic dru...

Daiichi Sankyo Company, Limited has launched a new formulation of LIXIANA 60mg Tablets, or edoxaban, in Japan for the recently approved indications of the prevention of ischemic stroke and systemic embolism in patients with non-valvular atrial ... Individual.com, 3 days ago
[x]  

7 images for daiichi sankyo company

Pharma Letter, 1 week ago
Drug Discovery and Development, 1 month ago
Reuters India, 2 months ago
Securities Technology Monitor, 2 months ago
Yahoo! News, 2 months ago
I Stock Analyst, 2 months ago
Securities Technology Monitor, 2 months ago
Pharma Letter

Daiichi Sankyo launches new generic drugs

Japanese pharma major Daiichi Sankyo (TYO: 4568) says its generics subsidiary, Daiichi Sankyo Espha, has launched nine new generic drugs with three new active ingredients Product names/therapeutic categories Product name Therapeutic ...
 Pharma Letter1 week ago Daiichi Sankyo introduces nine new generic drugs  PharmaBiz2 weeks ago

Daiichi Sankyo Company, Limited - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report

Project Synopsis: MarketLine's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its ...
 MarketResearch.com4 days ago Pieris Achieves GLP Tox Milestone Payment in Daiichi Sankyo Collaboration to Develop Anticalin(R)Therapeutics  CEOWorld Magazine2 weeks ago DAIICHI SANKYO : Pieris Achieves GLP Tox Milestone Payment  4 Traders2 weeks ago Daiichi Sankyo Company, Limited - Product Pipeline Review - 2014  Global Information Inc3 weeks ago
[x]  
Tutorial Finder

DAIICHI SANKYO : American Regent's Injectafer® ferric carboxymaltose injection Assigned J Code by Centers for Medicare & Medicaid Services

By a News Reporter-Staff News Editor at Managed Care Weekly Digest -- American Regent, Inc. , a subsidiary of Luitpold Pharmaceuticals, Inc. (a Daiichi Sankyo Group Company ), announced that the Centers for Medicare & Medicaid Services (CMS) has ...
 4 Traders4 days ago American Regent's Injectafer® (ferric carboxymaltose injection) Assigned J Code by Centers for Medicare & Medicaid Services  TickerTech.com1 week ago American Regent's Injectafer (ferric carboxymaltose injection) Assigned J Code by Centers for Medicare & Medicaid Services  Pharmacy Choice1 week ago American Regent's Injectafer?? (ferric carboxymaltose injection) Assigned J Code by Centers for Medicare & Medicaid Services  Tutorial Finder1 week ago
[x]  

Ambit Biosciences and Daiichi Sankyo, Inc. Announce Two Oral Presentations And One Poster Highlighting Quizartinib To Be Presented At The 56th Annual Meeting Of The American Society Of Hematology (ASH

SAN DIEGO and PARSIPPANY, N.J. , Dec. 4, 2014 /PRNewswire/ -- Ambit Biosciences, a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, and Daiichi Sankyo, ...
 Town Hall3 weeks ago DAIICHI SANKYO : Ambit Biosciences and Daiichi Sankyo, Inc. Announce Two Oral Presentations And One Poster Highlighting Quizartinib To Be Presented At The 56th Annual...  4 Traders3 weeks ago
[x]  

UCB-Daiichi Sankyo Ink Deal to Sell Vimpat in Japan - Analyst Blog

UCB SA ( UCBJF ) and Daiichi Sankyo Company, Ltd. announced that they have signed a deal to jointly commercialize Vimpat for the treatment of epilepsy in Japan. UCB intends to file for Vimpat in Japan and China as an adjunctive therapy for the ...
 Zacks.com3 weeks ago

Fortis HealthWorld Acquires Pharma Retail Chain CRS Health

This is the first acquisition of the Singh brothers after they sold Ranbaxy to Daiichi Sankyo. Ranbaxy Group promoted Fortis Healthworld has acquired 90 percent stake in CRS Health, a Delhi-based pharma and wellness retail chain for Rs 15 crore, ...
 VC Circle1 week ago

Ranbaxy gets approval to launch Synriam in African countries

Daiichi Sankyo-controlled Ranbaxy Laboratories has received the regulatory approval to launch India's first New Chemical Entity (NCE), Synriam (arterolane maleate 150 mg + piperaquine phosphate 750 mg drug) in seven African countries—Nigeria, ...
 VC Circle1 week ago Ranbaxy Commences Launch Of India's First NCE, Synriam In African Countries  FirstWord Pharma1 week ago Ranbaxy Laboratories : COMMENCES LAUNCH OF INDIA'S FIRST NCE, SYNRIAM IN AFRICAN COUNTRIES  4 Traders1 week ago
Rediff.com

Ranbaxy staff get pay-cut shield in Sun buyout

The agreement agreed to by Sun Pharmaceutical Industries for a buyout of Ranbaxy Laboratories from Daiichi Sankyo provides for a year's 'cooling period' during which the pay of Ranbaxy employees cannot be lowered, it is learnt. Ranbaxy is said to have also budgeted around Rs 65 crore for a retention bonus and identified 70-75 executives to distribute this. The year's cooling period is expected to start from the completion of the transaction between Sun and Daiichi, a source said. Ranbaxy ...
 Rediff.com2 months ago Sun Pharma Could Retire Brand Ranbaxy, Retain Sub-brands Like Volini And Revital  International Business Times India2 weeks ago Ranbaxy Posts Loss after Write-offs on US Import Bans  International Business Times India2 weeks ago Ranbaxy brand may fade away as Sun takes charge  Business Standard India2 weeks ago
[x]  

DAIICHI SANKYO : Plexxikon and QuantumLeap Healthcare Collaborative Select PLX3397 for I-SPY 2 Trial in Breast Cancer

Plexxikon and QuantumLeap Healthcare Collaborative said that Plexxikon's drug candidate, PLX3397, has been selected for study in the I-SPY 2 Trial (Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging And moLecular ...
 4 Traders1 week ago Plexxikon and QuantumLeap Healthcare Collaborative Announce Selection of PLX3397 for I-SPY 2 TRIAL in Breast Cancer  Pettinga Financial Advisors2 weeks ago Plexxikon Inc. And Collaborative Announce Selection Of PLX3397 For I-SPY 2 TRIAL In Breast Cancer  BioSpace2 weeks ago
[x]  
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less